101 related articles for article (PubMed ID: 35304155)
21. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder.
Wink LK; Adams R; Wang Z; Klaunig JE; Plawecki MH; Posey DJ; McDougle CJ; Erickson CA
Mol Autism; 2016; 7():26. PubMed ID: 27103982
[TBL] [Abstract][Full Text] [Related]
22. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
Grant JE; Chamberlain SR; Redden SA; Leppink EW; Odlaug BL; Kim SW
JAMA Psychiatry; 2016 May; 73(5):490-6. PubMed ID: 27007062
[TBL] [Abstract][Full Text] [Related]
23. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
24. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
25. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence.
Couto JP; Moreira R
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():245-254. PubMed ID: 29908912
[TBL] [Abstract][Full Text] [Related]
26. Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Kvale G; Hansen B; Hagen K; Abramowitz JS; Børtveit T; Craske MG; Franklin ME; Haseth S; Himle JA; Hystad S; Kristensen UB; Launes G; Lund A; Solem S; Öst LG
JAMA Netw Open; 2020 Aug; 3(8):e2013249. PubMed ID: 32789516
[TBL] [Abstract][Full Text] [Related]
27. Cognitive-behavioural therapy augments the effects of deep brain stimulation in obsessive-compulsive disorder.
Mantione M; Nieman DH; Figee M; Denys D
Psychol Med; 2014 Dec; 44(16):3515-22. PubMed ID: 25065708
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study.
Ellegaard PK; Licht RW; Nielsen RE; Dean OM; Berk M; Poulsen HE; Mohebbi M; Nielsen CT
J Affect Disord; 2019 Feb; 245():1043-1051. PubMed ID: 30699846
[TBL] [Abstract][Full Text] [Related]
29. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.
Berk M; Copolov DL; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Bush AI
Biol Psychiatry; 2008 Sep; 64(6):468-75. PubMed ID: 18534556
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
Jahanbakhsh SP; Manteghi AA; Emami SA; Mahyari S; Gholampour B; Mohammadpour AH; Sahebkar A
Complement Ther Med; 2016 Aug; 27():25-9. PubMed ID: 27515872
[TBL] [Abstract][Full Text] [Related]
31. Pregabalin augmentation for resistant obsessive-compulsive disorder: a double-blind placebo-controlled clinical trial.
Mowla A; Ghaedsharaf M
CNS Spectr; 2020 Aug; 25(4):552-556. PubMed ID: 31648655
[TBL] [Abstract][Full Text] [Related]
32. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial.
Berk M; Dean OM; Cotton SM; Gama CS; Kapczinski F; Fernandes B; Kohlmann K; Jeavons S; Hewitt K; Moss K; Allwang C; Schapkaitz I; Cobb H; Bush AI; Dodd S; Malhi GS
BMC Med; 2012 Aug; 10():91. PubMed ID: 22891797
[TBL] [Abstract][Full Text] [Related]
33. Placebo effect after prefrontal magnetic stimulation in the treatment of resistant obsessive-compulsive disorder: a randomized controlled trial.
Mansur CG; Myczkowki ML; de Barros Cabral S; Sartorelli Mdo C; Bellini BB; Dias AM; Bernik MA; Marcolin MA
Int J Neuropsychopharmacol; 2011 Nov; 14(10):1389-97. PubMed ID: 21557884
[TBL] [Abstract][Full Text] [Related]
34. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.
Sharafkhah M; Aghakarim Alamdar M; Massoudifar A; Abdolrazaghnejad A; Ebrahimi-Monfared M; Saber R; Mohammadbeigi A
Int Clin Psychopharmacol; 2019 Sep; 34(5):222-233. PubMed ID: 31058716
[TBL] [Abstract][Full Text] [Related]
35. Therapist-Guided, Internet-Delivered Cognitive-Behavioral Therapy for Adolescents With Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Lenhard F; Andersson E; Mataix-Cols D; Rück C; Vigerland S; Högström J; Hillborg M; Brander G; Ljungström M; Ljótsson B; Serlachius E
J Am Acad Child Adolesc Psychiatry; 2017 Jan; 56(1):10-19.e2. PubMed ID: 27993223
[TBL] [Abstract][Full Text] [Related]
36. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
[TBL] [Abstract][Full Text] [Related]
37. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E
Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510
[TBL] [Abstract][Full Text] [Related]
38. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.
McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Baker AL; Sinclair B; Reid D; Manning V; Te Pas N; Liang W; Thomas T; Bathish R; Kent M; Raftery D; Arunogiri S; Cordaro F; Hill H; Berk M
Trials; 2019 Jun; 20(1):325. PubMed ID: 31164169
[TBL] [Abstract][Full Text] [Related]
39. What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review.
Smith L; Tracy DK; Giaroli G
J Clin Psychopharmacol; 2016 Feb; 36(1):57-62. PubMed ID: 26629962
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
